The cost of systemic corticosteroid-induced morbidity in severe asthma: a health economic analysis
Uloženo v:
| Název: | The cost of systemic corticosteroid-induced morbidity in severe asthma: a health economic analysis |
|---|---|
| Autoři: | J Sweeney, Luke Barry, Ciaran O'Neill, Liam G Heaney, David Price |
| Přispěvatelé: | University of Galway Research Repository, University of Aberdeen.Other Applied Health Sciences, University of Aberdeen.Institute of Applied Health Sciences |
| Zdroj: | Respir Res Respiratory Research, Vol 18, Iss 1, Pp 1-8 (2017) Barry, L, Sweeney, J, O'Neill, C, Price, D & Heaney, L G 2017, 'The cost of systemic corticosteroid-induced morbidity in severe asthma: a health economic analysis', Respiratory Research, vol. 18, no. 1, pp. 129-137. https://doi.org/10.1186/s12931-017-0614-x, https://doi.org/10.1186/s12931-017-0614-x |
| Informace o vydavateli: | Springer Science and Business Media LLC, 2017. |
| Rok vydání: | 2017 |
| Témata: | Oral, Adult, Male, Factual/trends, Databases, Factual, Administration, Oral, Comorbidity, severe refractory asthma, R Medicine, registry, Asthma/diagnosis, Systemic Corticosteroids, Severity of Illness Index, Cohort Studies, Databases, Diseases of the respiratory system, 03 medical and health sciences, Adrenal Cortex Hormones/administration & dosage, Health Economics, 0302 clinical medicine, Adrenal Cortex Hormones, Journal Article, Anti-Asthmatic Agents/administration & dosage, Humans, health economics, Anti-Asthmatic Agents, uk, Aged, RC705-779, Research, Health Care Costs, Middle Aged, asthma, systemic corticosteroids, Asthma, 3. Good health, comorbidity, Administration, Databases, Factual/trends, Female, Health Care Costs/trends |
| Popis: | Background: Treatment of severe asthma may include high dose systemic-steroid therapy which is associated with substantial additional morbidity. This study estimates the additional healthcare costs associated with steroid-induced morbidity by comparing three patients groups: those with severe asthma, moderate asthma and no asthma. Methods: Patients with severe asthma (n = 808, GINA step 5 treatment) were matched by age and gender with patients with mild/moderate asthma (n = 3,975, GINA step 2 and 3 treatment) and a non-asthma control cohort (with a diagnosis of rhinitis; n = 2,412) from the Optimum Patient Care Research Database (OPCRD), a nationally representative primary care database. Prescribed drugs and publicly funded healthcare activity were monetised and annual costs per patient estimated. Regression analyses were used to estimate the additional healthcare cost associated with steroid-induced morbidity. Results: Average healthcare costs per person per year range from 2603 pound - 4533 pound for the severe asthma cohort, to 978 pound - 2072 pound for the mild/moderate asthma cohort, to 560 pound - 1324 pound for the non-asthma control cohort, depending on the costing scenario. Differences in induced morbidity costs were evident between patients with asthma differentiated by steroid exposure. In relation to prescription drugs used to treat steroid-induced co-morbidities, females with severe asthma and high steroid exposure cost approximately 789 pound more per year than a corresponding female with no asthma, while males cost approximately 744 pound more than their counterparts with no asthma. Estimates were extrapolated to all healthcare costs. Conclusions: This study provides the first robust estimates of the additional cost of healthcare related to steroid-induced morbidity relative to patients with no steroid exposure. The study will help inform use of steroid-sparing strategies in this patient group. |
| Druh dokumentu: | Article Other literature type |
| Popis souboru: | application/pdf |
| Jazyk: | English |
| ISSN: | 1465-993X |
| DOI: | 10.1186/s12931-017-0614-x |
| DOI: | 10.13025/25865 |
| Přístupová URL adresa: | https://respiratory-research.biomedcentral.com/track/pdf/10.1186/s12931-017-0614-x https://pubmed.ncbi.nlm.nih.gov/28651591 https://doaj.org/article/9ca98672b3214938b7f1c89dff684685 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485660 https://core.ac.uk/display/131024040 https://aura.abdn.ac.uk/bitstream/2164/8986/1/The_cost_of_systemic_corticosteroid_induced_morbidity_in_severe_asthma_a_health_economic_analysis.pdf https://pure.qub.ac.uk/en/publications/the-cost-of-systemic-corticosteroid-induced-morbidity-in-severe-a https://aura.abdn.ac.uk/handle/2164/8986?show=full https://pure.qub.ac.uk/en/publications/48990a98-20d9-4d10-97b2-2b0c47846317 |
| Rights: | CC BY CC BY NC ND |
| Přístupové číslo: | edsair.doi.dedup.....26618d59097e1158fc0bef6fc9fd4b49 |
| Databáze: | OpenAIRE |
Full Text 
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | Background: Treatment of severe asthma may include high dose systemic-steroid therapy which is associated with substantial additional morbidity. This study estimates the additional healthcare costs associated with steroid-induced morbidity by comparing three patients groups: those with severe asthma, moderate asthma and no asthma. Methods: Patients with severe asthma (n = 808, GINA step 5 treatment) were matched by age and gender with patients with mild/moderate asthma (n = 3,975, GINA step 2 and 3 treatment) and a non-asthma control cohort (with a diagnosis of rhinitis; n = 2,412) from the Optimum Patient Care Research Database (OPCRD), a nationally representative primary care database. Prescribed drugs and publicly funded healthcare activity were monetised and annual costs per patient estimated. Regression analyses were used to estimate the additional healthcare cost associated with steroid-induced morbidity. Results: Average healthcare costs per person per year range from 2603 pound - 4533 pound for the severe asthma cohort, to 978 pound - 2072 pound for the mild/moderate asthma cohort, to 560 pound - 1324 pound for the non-asthma control cohort, depending on the costing scenario. Differences in induced morbidity costs were evident between patients with asthma differentiated by steroid exposure. In relation to prescription drugs used to treat steroid-induced co-morbidities, females with severe asthma and high steroid exposure cost approximately 789 pound more per year than a corresponding female with no asthma, while males cost approximately 744 pound more than their counterparts with no asthma. Estimates were extrapolated to all healthcare costs. Conclusions: This study provides the first robust estimates of the additional cost of healthcare related to steroid-induced morbidity relative to patients with no steroid exposure. The study will help inform use of steroid-sparing strategies in this patient group. |
|---|---|
| ISSN: | 1465993X |
| DOI: | 10.1186/s12931-017-0614-x |